| MIR27A | microRNA 27a | MIR27A can be both a tumor-suppressor and an oncogene. For instance, the expression of miR-27a is significantly lower in acute leukemia compared to normal cells. It has been shown that miRNA-27a inhibits cell growth and promotes apoptosis by targeting 14-3-3θ, a member of 14-3-3 family of anti-apoptotic proteins. [23236401]. Therefore, it acts as a tumor-suppressor in leukemia. However, in gastric cancer mir-27a acts as an oncogene by targeting inhibiting and thus promoting cancer cell growth [18789835]. | Human |
| miR152 | microRNA 152 | MiR152 belongs to miR148/152 cluster and can act as a tumor-suppressor. In ovarian cancer, miR152 suppresses DNMT1 directly and inhibits proliferation of cancer cells. [23318422] The miRNA is downregulated in ovarian cancer cells lines and its downregulation may lead to deregulation of cell proliferation in ovarian cancer. [21971665]
| Human |
| miR148b | microRNA 148b | Mir148b belongs to mir148/152 cluster and acts as a tumor-suppressor in certain types of cancer. As a result of a study of miR148b expression in gastric cancer it has been determined that in 62 percent of cases, in tumor tissue miRNA was downregulated compared to adjacent non-tumor tissue. MiR148b suppresses tumorigenecity by targeting CCKBR, whose action is to mediate the function of gastrin, which has proliferative effects. |21205300] In addition, while miR148b is downregulated in pancreatic cancer tissues, its overexpression inhibits invasion and increases chemosensitivity [23171948]. | Human |
| miR148a | microRNA 148a | miR148a belongs to miR148-152 cluster and acts as a tumor-suppressor in different types of cancer. MiR148a expression is suppressed more than 4-fold in gastric cancer. An inverse correlation has been observed between miR148a expression and lymph node metastasis in gastric cancer. Mir148a suppresses migratory abilities of cancer cells and metastasis formation by downregulating the oncogene ROCK1 expression [21994419]. miR148a is downregulated in pancreatic ductal adenocarcinoma (PDAC). it has been shown that miR148a directly targets the 3'UTR region of CDC25B mRNA. CDC25B is a phosphatase that, by activating a cyclin-CDK complex, initiates mitosis, therefore CDC25B suppression by miR148a could have a tumor-suppressor effect on PDAC. [21709669] | Human |
| hsa-let-7c | microRNA let-7c | let-7c is downregulated in prostate cancer, which increases cell proliferation [22479342]. More specifically, let-7c is a regulator of androgen receptor (AR), which plays a role in the development of prostate cancer [22128178]. | Human |
| hsa-let-7b | microRNA let-7b | Let-7b, a member of the let-7 group, appears to be a tumor-suppressor. In acute lymphoblastic leukemia, let-7b is severely downregulated and its overexpression inhibits cancer cells growth [22918121]. In melanoma cells, the miRNA downregulates the expression of cell cycle regulators such as cyclin D1, D3, and A and Cdk4, which inhibits cell cycle progression. [18379589] | Human |
| hsa-let-7a | microRNA let-7a | A tumor-suppressor downregulated in different types of cancer. Let-7a binds to 3'-UTR region of RAB40C, thus leading to a decrease in cell proliferation and an increase of G1 arrest in human gastric carcinomas [20809749, 21349817]. In human breast cancer, evidence suggests that members of let-7 family inhibit breast cancer cell migration by targeting genes responsible for actin dynamics [23339187]. Moreover, let-7a directly targets CCR7, a receptor that promotes invasiveness of cancer cells [23335963] | Human |
| MIR145 | microRNA 145 | MIR145 is a tumor suppressor that acts by inhibiting IRS-1 in human colon cancer cells. It also targets IGFR1 [17827156; 19391107]. It decreases cell migration in gliomas by targeting CTGF, metastasis and migration-promoting gene. MIR145 is downregulated in astrocytic tumors and oligodendrogliomas [23390502;
23577178]. | Human |
| MIR16-1 | microRNA16-1 | MIR16-1 is a tumor-suppressor downregulated in different types of cancers. In chronic lymphocytic leukemia (CLL) it is downregulated in 68% of cases [12434020]. MIR16-1 may post-transcriptionally downregulate the expression of Bcl2, thus inducing apoptosis. Therefore, inactivation of MIR15A and MIR16-1 in CLL lymphocytes results in a reduced apoptosis rate [16166262].
In prostate cancer, MIR15A and MIR16-1 are downregulated, which results in decreased repression of FGF-2, thus promoting tumor expansion and invasiveness [21532615].
MIR15A and MIR16-1 are also downregulated in pituitary adenomas as thier expression exhibits an inverse correlation with tumor diameter, therefore possible influence on tumor growth [15648093]. | Human |
| MIR15A | microRNA 15a | MIR15A is a tumor-suppressor downregulated in different types of cancers. In chronic lymphocytic leukemia (CLL) it is downregulated in 68% of cases [12434020]. MIR15A may post-transcriptionally downregulate the expression of Bcl2, thus inducing apoptosis. Therefore, inactivation of MIR15A and MIR16-1 in CLL lymphocytes results in a reduced apoptosis rate [16166262].
In prostate cancer, MIR15A and MIR16-1 are downregulated, which results in decreased repression of FGF-2, thus promoting tumor expansion and invasiveness [21532615].
MIR15A and MIR16-1 are also downregulated in pituitary adenomas as thier expression exhibits an inverse correlation with tumor diameter, therefore possible influence on tumor growth [15648093]. | Human |
| MIR29A | microRNA 29a | miR-29a reduces the amount of methylation and upregulates a long non-coding RNA form a region called MEG3 that is responsible for inducing apoptotic pathway. Thus reducing tumorgensis in non-malignant hepatocytes [21625215].
| Human |
| BUB1B | budding uninhibited by benzimidazoles 1 homolog beta (yeast) | Mutations in BUB1B are associated with mosaic variegated aneuplody, a rare human syndrome characterized by aneuplodization, tumour predisposition and several progeroid traits, including short lifespan, growth and mental retardation, cataracts and facial dysmorphisms [16411201; 15475955; 20651707]. | Human |
| SIRT6 | sirtuin 6 | SIRT6 is a critical modulator of cancer metabolism. SIRT6 is selectively downregulated in several cancers. Expression of SIRT6 predicts prognosis of tumor-free survival rates [23217706]. | Human |
